Henry Schein, Inc.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, MCK has a market cap of 88.60B. Regarding current trading prices, HSIC is priced at $66.58, while MCK trades at $706.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas MCK's P/E ratio is 32.39. In terms of profitability, HSIC's ROE is +0.11%, compared to MCK's ROE of -1.15%. Regarding short-term risk, HSIC is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, COR has a market cap of 56.61B. Regarding current trading prices, HSIC is priced at $66.58, while COR trades at $291.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas COR's P/E ratio is 41.47. In terms of profitability, HSIC's ROE is +0.11%, compared to COR's ROE of +1.85%. Regarding short-term risk, HSIC is more volatile compared to COR. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, CAH has a market cap of 36.72B. Regarding current trading prices, HSIC is priced at $66.58, while CAH trades at $152.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas CAH's P/E ratio is 23.82. In terms of profitability, HSIC's ROE is +0.11%, compared to CAH's ROE of -0.50%. Regarding short-term risk, HSIC is more volatile compared to CAH. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, ABC has a market cap of 36.15B. Regarding current trading prices, HSIC is priced at $66.58, while ABC trades at $179.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas ABC's P/E ratio is 21.92. In terms of profitability, HSIC's ROE is +0.11%, compared to ABC's ROE of +1.72%. Regarding short-term risk, HSIC is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, SHPMY has a market cap of 8.49B. Regarding current trading prices, HSIC is priced at $66.58, while SHPMY trades at $7.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas SHPMY's P/E ratio is 9.69. In terms of profitability, HSIC's ROE is +0.11%, compared to SHPMY's ROE of +0.06%. Regarding short-term risk, HSIC is more volatile compared to SHPMY. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, SHPMF has a market cap of 8.13B. Regarding current trading prices, HSIC is priced at $66.58, while SHPMF trades at $1.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas SHPMF's P/E ratio is 10.47. In terms of profitability, HSIC's ROE is +0.11%, compared to SHPMF's ROE of +0.06%. Regarding short-term risk, HSIC is more volatile compared to SHPMF. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, SHTDY has a market cap of 8.04B. Regarding current trading prices, HSIC is priced at $66.58, while SHTDY trades at $12.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas SHTDY's P/E ratio is 6.72. In terms of profitability, HSIC's ROE is +0.11%, compared to SHTDY's ROE of +0.09%. Regarding short-term risk, HSIC is more volatile compared to SHTDY. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, SHTDF has a market cap of 7.64B. Regarding current trading prices, HSIC is priced at $66.58, while SHTDF trades at $2.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas SHTDF's P/E ratio is 6.45. In terms of profitability, HSIC's ROE is +0.11%, compared to SHTDF's ROE of +0.06%. Regarding short-term risk, HSIC is more volatile compared to SHTDF. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, CAKFY has a market cap of 5.37B. Regarding current trading prices, HSIC is priced at $66.58, while CAKFY trades at $4.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas CAKFY's P/E ratio is -68.33. In terms of profitability, HSIC's ROE is +0.11%, compared to CAKFY's ROE of -0.02%. Regarding short-term risk, HSIC is more volatile compared to CAKFY. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, AMFPF has a market cap of 4.28B. Regarding current trading prices, HSIC is priced at $66.58, while AMFPF trades at $19.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas AMFPF's P/E ratio is 26.03. In terms of profitability, HSIC's ROE is +0.11%, compared to AMFPF's ROE of +0.13%. Regarding short-term risk, HSIC is more volatile compared to AMFPF. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, PBH has a market cap of 4.11B. Regarding current trading prices, HSIC is priced at $66.58, while PBH trades at $82.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas PBH's P/E ratio is 19.47. In terms of profitability, HSIC's ROE is +0.11%, compared to PBH's ROE of +0.12%. Regarding short-term risk, HSIC is more volatile compared to PBH. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, GALNF has a market cap of 3.75B. Regarding current trading prices, HSIC is priced at $66.58, while GALNF trades at $75.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas GALNF's P/E ratio is 20.23. In terms of profitability, HSIC's ROE is +0.11%, compared to GALNF's ROE of +0.12%. Regarding short-term risk, HSIC is more volatile compared to GALNF. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, MAHLY has a market cap of 3.40B. Regarding current trading prices, HSIC is priced at $66.58, while MAHLY trades at $16.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas MAHLY's P/E ratio is 9.91. In terms of profitability, HSIC's ROE is +0.11%, compared to MAHLY's ROE of +0.06%. Regarding short-term risk, HSIC is more volatile compared to MAHLY. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, MEPDF has a market cap of 3.08B. Regarding current trading prices, HSIC is priced at $66.58, while MEPDF trades at $14.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas MEPDF's P/E ratio is 8.97. In terms of profitability, HSIC's ROE is +0.11%, compared to MEPDF's ROE of +0.08%. Regarding short-term risk, HSIC is more volatile compared to MEPDF. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, PDCO has a market cap of 2.77B. Regarding current trading prices, HSIC is priced at $66.58, while PDCO trades at $31.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas PDCO's P/E ratio is 20.48. In terms of profitability, HSIC's ROE is +0.11%, compared to PDCO's ROE of +0.14%. Regarding short-term risk, HSIC is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, ALFRY has a market cap of 2.44B. Regarding current trading prices, HSIC is priced at $66.58, while ALFRY trades at $13.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas ALFRY's P/E ratio is 12.90. In terms of profitability, HSIC's ROE is +0.11%, compared to ALFRY's ROE of +0.05%. Regarding short-term risk, HSIC is more volatile compared to ALFRY. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, ARHCF has a market cap of 2.27B. Regarding current trading prices, HSIC is priced at $66.58, while ARHCF trades at $11.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas ARHCF's P/E ratio is 9.97. In terms of profitability, HSIC's ROE is +0.11%, compared to ARHCF's ROE of +0.05%. Regarding short-term risk, HSIC is more volatile compared to ARHCF. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, SZUKF has a market cap of 1.72B. Regarding current trading prices, HSIC is priced at $66.58, while SZUKF trades at $30.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas SZUKF's P/E ratio is 11.43. In terms of profitability, HSIC's ROE is +0.11%, compared to SZUKF's ROE of +0.04%. Regarding short-term risk, HSIC is more volatile compared to SZUKF. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, IUSDF has a market cap of 1.66B. Regarding current trading prices, HSIC is priced at $66.58, while IUSDF trades at $23.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas IUSDF's P/E ratio is 30.05. In terms of profitability, HSIC's ROE is +0.11%, compared to IUSDF's ROE of +0.12%. Regarding short-term risk, HSIC is less volatile compared to IUSDF. This indicates potentially lower risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, GRDN has a market cap of 1.60B. Regarding current trading prices, HSIC is priced at $66.58, while GRDN trades at $25.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas GRDN's P/E ratio is -14.16. In terms of profitability, HSIC's ROE is +0.11%, compared to GRDN's ROE of -1.16%. Regarding short-term risk, HSIC is more volatile compared to GRDN. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, MEDOF has a market cap of 1.28B. Regarding current trading prices, HSIC is priced at $66.58, while MEDOF trades at $50.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas MEDOF's P/E ratio is 73.53. In terms of profitability, HSIC's ROE is +0.11%, compared to MEDOF's ROE of +0.03%. Regarding short-term risk, HSIC is less volatile compared to MEDOF. This indicates potentially lower risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, ARRJF has a market cap of 836.17M. Regarding current trading prices, HSIC is priced at $66.58, while ARRJF trades at $3.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas ARRJF's P/E ratio is 18.06. In terms of profitability, HSIC's ROE is +0.11%, compared to ARRJF's ROE of +0.06%. Regarding short-term risk, HSIC is less volatile compared to ARRJF. This indicates potentially lower risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, OMI has a market cap of 628.85M. Regarding current trading prices, HSIC is priced at $66.58, while OMI trades at $8.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas OMI's P/E ratio is -1.72. In terms of profitability, HSIC's ROE is +0.11%, compared to OMI's ROE of -0.45%. Regarding short-term risk, HSIC is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, WGRX has a market cap of 237.39M. Regarding current trading prices, HSIC is priced at $66.58, while WGRX trades at $4.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas WGRX's P/E ratio is -30.47. In terms of profitability, HSIC's ROE is +0.11%, compared to WGRX's ROE of -1.74%. Regarding short-term risk, HSIC is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, ZYXI has a market cap of 63.65M. Regarding current trading prices, HSIC is priced at $66.58, while ZYXI trades at $2.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas ZYXI's P/E ratio is 23.39. In terms of profitability, HSIC's ROE is +0.11%, compared to ZYXI's ROE of -0.24%. Regarding short-term risk, HSIC is less volatile compared to ZYXI. This indicates potentially lower risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, GEG has a market cap of 53.85M. Regarding current trading prices, HSIC is priced at $66.58, while GEG trades at $1.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas GEG's P/E ratio is -190.00. In terms of profitability, HSIC's ROE is +0.11%, compared to GEG's ROE of +0.00%. Regarding short-term risk, HSIC is more volatile compared to GEG. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, HX has a market cap of 53.37M. Regarding current trading prices, HSIC is priced at $66.58, while HX trades at $2.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas HX's P/E ratio is -1.84. In terms of profitability, HSIC's ROE is +0.11%, compared to HX's ROE of -0.04%. Regarding short-term risk, HSIC is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, EXHI has a market cap of 15.06M. Regarding current trading prices, HSIC is priced at $66.58, while EXHI trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas EXHI's P/E ratio is N/A. In terms of profitability, HSIC's ROE is +0.11%, compared to EXHI's ROE of +0.00%. Regarding short-term risk, HSIC is more volatile compared to EXHI. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, NSVGF has a market cap of 8.48M. Regarding current trading prices, HSIC is priced at $66.58, while NSVGF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas NSVGF's P/E ratio is -1.00. In terms of profitability, HSIC's ROE is +0.11%, compared to NSVGF's ROE of +0.21%. Regarding short-term risk, HSIC is less volatile compared to NSVGF. This indicates potentially lower risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, ENMI has a market cap of 7.66M. Regarding current trading prices, HSIC is priced at $66.58, while ENMI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas ENMI's P/E ratio is -0.20. In terms of profitability, HSIC's ROE is +0.11%, compared to ENMI's ROE of +0.51%. Regarding short-term risk, HSIC is more volatile compared to ENMI. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, RDGT has a market cap of 6.44M. Regarding current trading prices, HSIC is priced at $66.58, while RDGT trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas RDGT's P/E ratio is -0.33. In terms of profitability, HSIC's ROE is +0.11%, compared to RDGT's ROE of N/A. Regarding short-term risk, HSIC is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, PDRX has a market cap of 4.26M. Regarding current trading prices, HSIC is priced at $66.58, while PDRX trades at $2.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas PDRX's P/E ratio is 2.56. In terms of profitability, HSIC's ROE is +0.11%, compared to PDRX's ROE of -0.07%. Regarding short-term risk, HSIC is more volatile compared to PDRX. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, KOSK has a market cap of 3.98M. Regarding current trading prices, HSIC is priced at $66.58, while KOSK trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas KOSK's P/E ratio is -0.18. In terms of profitability, HSIC's ROE is +0.11%, compared to KOSK's ROE of -0.13%. Regarding short-term risk, HSIC is more volatile compared to KOSK. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, ITNS has a market cap of 533194.00. Regarding current trading prices, HSIC is priced at $66.58, while ITNS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas ITNS's P/E ratio is -0.03. In terms of profitability, HSIC's ROE is +0.11%, compared to ITNS's ROE of +0.01%. Regarding short-term risk, HSIC is less volatile compared to ITNS. This indicates potentially lower risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, PHRX has a market cap of 5171.00. Regarding current trading prices, HSIC is priced at $66.58, while PHRX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas PHRX's P/E ratio is N/A. In terms of profitability, HSIC's ROE is +0.11%, compared to PHRX's ROE of +0.85%. Regarding short-term risk, HSIC is less volatile compared to PHRX. This indicates potentially lower risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, CHME has a market cap of 2380.00. Regarding current trading prices, HSIC is priced at $66.58, while CHME trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas CHME's P/E ratio is N/A. In terms of profitability, HSIC's ROE is +0.11%, compared to CHME's ROE of +0.04%. Regarding short-term risk, HSIC is more volatile compared to CHME. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, MLTO has a market cap of 1700.00. Regarding current trading prices, HSIC is priced at $66.58, while MLTO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas MLTO's P/E ratio is -0.00. In terms of profitability, HSIC's ROE is +0.11%, compared to MLTO's ROE of N/A. Regarding short-term risk, HSIC is less volatile compared to MLTO. This indicates potentially lower risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, TGVN has a market cap of 120.00. Regarding current trading prices, HSIC is priced at $66.58, while TGVN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas TGVN's P/E ratio is -0.00. In terms of profitability, HSIC's ROE is +0.11%, compared to TGVN's ROE of N/A. Regarding short-term risk, HSIC is more volatile compared to TGVN. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.

HSIC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HSIC stands at 8.16B. In comparison, CVET comparison data is unavailable. Regarding current trading prices, HSIC is priced at $66.58, while CVET trades at $20.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HSIC currently has a P/E ratio of 21.83, whereas CVET's P/E ratio is -69.97. In terms of profitability, HSIC's ROE is +0.11%, compared to CVET's ROE of -0.06%. Regarding short-term risk, HSIC is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for HSIC.